论文部分内容阅读
目的 :评价国产与进口干扰素治疗慢性丙型肝炎的疗效与安全性。方法 :对 6 4例住院接受干扰素治疗的慢性丙型肝炎患者进行分析。其中国产干扰素治疗 35例 ,进口干扰素治疗 2 9例。以血清丙氨酸转氨酶(ALT)复常及丙型肝炎病毒核糖核酸 (HCV RNA)聚合酶链反应检查阴转评价药物疗效 ,同时观察不良反应。结果 :国产与进口两组患者血清ALT复常率分别为 6 8.6 %及 6 9%、HCV RNA阴转率分别为 6 2 .9%及 5 8.6 % ,无显著性差异 (P >0 .0 5 )。近期疗效两组亦无显著性差异 (P >0 .0 5 )。两组干扰素治疗期间主要不良反应发生的类型、频率均无显著性差异。结论 :国产与进口干扰素治疗慢性丙型肝炎同样有效、安全。
Objective: To evaluate the efficacy and safety of domestic and imported interferon in the treatment of chronic hepatitis C Methods: Sixty-four patients with chronic hepatitis C admitted to hospital for interferon therapy were analyzed. Among them, 35 cases were treated with interferon and 29 cases were treated with imported interferon. Serum alanine aminotransferase (ALT) normal and hepatitis C virus RNA (HCV RNA) polymerase chain reaction test negative evaluation of drug efficacy, and observed adverse reactions. Results: The rates of abnormal ALT in both domestic and imported patients were 66.6% and 69%, respectively. The negative rates of HCV RNA were 62.9% and 58.6% respectively, with no significant difference (P> 0.05) 5). There was no significant difference between the two groups in the short term efficacy (P> 0.05). There was no significant difference in the type and frequency of major adverse reactions between the two groups of interferon therapy. Conclusion: Domestic and imported interferon are equally effective and safe in the treatment of chronic hepatitis C.